Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CingulateCING -5.58%36 EV-to-OCF is -2.20 as of Jul. 24, 2026. GuruFocus rates CING with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,410 Biotechnology companies, Cingulate ranks worse than 55.46% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cingulate's Enterprise Value is $43.09 Mil.
Cingulate's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.55 Mil. Therefore, Cingulate's EV-to-OCF for today is -2.20.
The historical rank and industry rank for Cingulate's EV-to-OCF or its related term are showing as below:
CING'
s EV-to-OCF Range Over the Past 10 Years
Min: -2.39 Med: 0 Max: -2.19
Current: -2.2
During the past 7 years, the highest EV-to-OCF of Cingulate was -2.19. The lowest was -2.39. And the median was .
CING's EV-to-OCF is ranked worse than 55.46% of 1410
companies
in the Biotechnology industry
Industry Median: -3.315
vs CING: -2.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cingulate's share price for today is $4.57.
Cingulate's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.255.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cingulate EV-to-OCF Related Terms
Cingulate EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cingulate's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cingulate's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cingulate EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cingulate's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cingulate's EV-to-OCF falls into.
Cingulate's current Enterprise Value is $43.09 Mil.
Cingulate's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cingulate (CING) has a EV-to-OCF of -2.20 as of Jul. 24, 2026. According to the industry distribution chart, Cingulate ranks #782 out of 1410 companies in the Biotechnology industry, placing it in the top 55.5%.
Is Cingulate's EV-to-OCF too high?
Cingulate's current EV-to-OCF is -2.20. Based on the distribution chart, Cingulate ranks #782 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cingulate has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Cingulate's EV-to-OCF compare to IMA and MCRB?
According to the Biotechnology industry distribution chart, Cingulate ranks #782 out of 1410 companies for EV-to-OCF. This places Cingulate in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cingulate's current EV-to-OCF is -2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cingulate stock overvalued right now?
Cingulate (CING) has a current EV-to-OCF of -2.20. The current EV-to-OCF is -2.20. Cingulate's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cingulate (CING), the current EV-to-OCF is -2.20 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
36GF Score
Get the complete analysis for CING
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CING has been successfully added to your 
